EVOK — Evoke Pharma Balance Sheet
0.000.00%
- $18.86m
- $12.28m
- $10.25m
- 35
- 30
- 82
- 47
Annual balance sheet for Evoke Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 8.07 | 9.14 | 9.84 | 4.74 | 13.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.023 | 0.295 | 0.625 | 0.673 | 2.42 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 9.28 | 10.6 | 11.7 | 6.83 | 17.2 |
| Net Property, Plant And Equipment | 0.142 | 0.012 | 0.129 | 0 | 0.154 |
| Other Long Term Assets | |||||
| Total Assets | 9.43 | 10.6 | 11.9 | 7.07 | 17.5 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.54 | 1.41 | 1.65 | 3.04 | 10.4 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 12.6 | 7.02 | 7.77 | 9.65 | 10.5 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -3.21 | 3.56 | 4.08 | -2.58 | 7.04 |
| Total Liabilities & Shareholders' Equity | 9.43 | 10.6 | 11.9 | 7.07 | 17.5 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |